Skip to main content
. 2018 Oct 27;58(5):651–658. doi: 10.1007/s40262-018-0719-5

Table 2.

Patient characteristics

Characteristics No. of patients (%)
Original study
 Pazopanib TDM [17] 13 (14)
 Phase I with docetaxel [1] 40 (43)
 Phase I with ifosfamide [2] 41 (44)
Sex
 Male 67 (71)
 Female 27 (29)
Age, y, median (IQR) 57 (48–64)
Pazopanib starting dose (mg QD)
 200 18 (19)
 400 38 (40)
 600
 800
3 (3)
20 (21)
 1000 15 (16)
Ethnicity
 Caucasian 91 (97)
 Asian 2 (2)
 Black 1 (1)

IQR inter-quartile range, QD quoque dies (once daily), TDM therapeutic drug monitoring